Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m2 in Ontario, Canada.
Rapattoni W, Zante D, Tomas M, Myageri V, Golden S, Grover P, Tehrani A, Millson B, Tobe SW, Rose JB. Rapattoni W, et al. Diabetes Obes Metab. 2021 Apr;23(4):916-928. doi: 10.1111/dom.14294. Epub 2021 Jan 13. Diabetes Obes Metab. 2021. PMID: 33319487 Free PMC article.
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD, Rose JB, Rapattoni W, Bajaj HS. Woo V, et al. Among authors: rapattoni w. Diabetes Obes Metab. 2019 Mar;21(3):691-699. doi: 10.1111/dom.13573. Epub 2018 Dec 5. Diabetes Obes Metab. 2019. PMID: 30393961 Free PMC article.
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
Tsoukas MA, Woo V, Tobe SW, Slee A, Rapattoni W, Ang FG, Seufert J, Neuen BL, Arnott C, Mahaffey KW, Wheeler DC. Tsoukas MA, et al. Among authors: rapattoni w. Diabetes Obes Metab. 2023 Jul;25(7):2038-2042. doi: 10.1111/dom.15057. Epub 2023 Apr 4. Diabetes Obes Metab. 2023. PMID: 36942888 No abstract available.
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Sharma A, Marques P, Neuen BL, Fletcher RA, Slee A, Rapattoni W, Ang FG, Arnott C, Levin A, Verma S, Perkovic V, Mahaffey KW. Sharma A, et al. Among authors: rapattoni w. Diabetes Obes Metab. 2024 Feb;26(2):758-762. doi: 10.1111/dom.15340. Epub 2023 Oct 26. Diabetes Obes Metab. 2024. PMID: 37881140 No abstract available.
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
Yi TW, Wong MMY, Neuen BL, Arnott C, Poirier P, Seufert J, Slee A, Rapattoni W, Ang FG, Wheeler DC, Mahaffey KW, Perkovic V, Levin A. Yi TW, et al. Among authors: rapattoni w. Diabetes Obes Metab. 2023 Jul;25(7):2043-2047. doi: 10.1111/dom.15065. Epub 2023 Apr 24. Diabetes Obes Metab. 2023. PMID: 36974373 No abstract available.
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
Sharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GBJ, Wong NC, Slee A, Ang FG, Rapattoni W, Neuen BL, Arnott C, Perkovic V, Mahaffey KW. Sharma A, et al. Among authors: rapattoni w. J Am Heart Assoc. 2024 Feb 6;13(3):e031586. doi: 10.1161/JAHA.123.031586. Epub 2024 Jan 19. J Am Heart Assoc. 2024. PMID: 38240199 Free PMC article.